Document/ExhibitDescriptionPagesSize 1: 10-Q Quarterly Report HTML 657K
2: EX-10.1 Material Contract HTML 46K
3: EX-31 Certification -- §302 - SOA'02 HTML 28K
4: EX-32 Certification -- §906 - SOA'02 HTML 21K
11: R1 Document and Entity Information HTML 72K
12: R2 Condensed Consolidated Balance Sheets HTML 111K
13: R3 Condensed Consolidated Balance Sheets HTML 30K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 81K
15: R5 Condensed Consolidated Statements of Comprehensive HTML 42K
Income
16: R6 Condensed Consolidated Statements of Cash Flows HTML 97K
17: R7 Consolidated Statements of Stockholder's Equity HTML 71K
Consolidated Statements of Stockholder's Equity
18: R8 Consolidated Statements of Stockholder's Equity HTML 20K
(Parenthetical)
19: R9 Basis of Presentation HTML 20K
20: R10 Recently Adopted and New Accounting Standards New HTML 29K
Accounting Pronouncements (Notes)
21: R11 Fair Value Measurements HTML 28K
22: R12 Receivables, net (Notes) HTML 27K
23: R13 Inventories HTML 25K
24: R14 Leases HTML 65K
25: R15 Debt HTML 61K
26: R16 Income Taxes HTML 22K
27: R17 Other Operating Charges, net (Notes) HTML 21K
28: R18 Non-operating Income (Expense) (Notes) HTML 39K
29: R19 Accumulated Other Comprehensive Loss (Notes) HTML 35K
30: R20 Stockholders' Equity HTML 31K
31: R21 Earnings per Common Share HTML 30K
32: R22 Segment Information HTML 60K
33: R23 Receivables, net (Tables) HTML 27K
34: R24 Inventories - (Tables) HTML 26K
35: R25 Leases - (Tables) HTML 68K
36: R26 Debt Debt Disclosures (Tables) HTML 52K
37: R27 Other Operating Charges, net (Tables) HTML 34K
38: R28 Non-operating Income (Expense) (Tables) HTML 38K
39: R29 Pension and Other Postretirement Employee Benefit HTML 50K
Plans - (Tables)
40: R30 Accumulated Other Comprehensive Loss (Tables) HTML 34K
41: R31 Stockholders' Equity - (Tables) HTML 31K
42: R32 Earnings per Common Share - (Tables) HTML 29K
43: R33 Segment Information - (Tables) HTML 59K
44: R34 Fair Value Measurements (Detail) HTML 27K
45: R35 Receivables, net (Details) HTML 32K
46: R36 Inventories - Inventories (Details) HTML 26K
47: R37 Leases - Narrative (Detail) HTML 119K
48: R38 Debt (Detail) HTML 102K
49: R39 Debt - Additional Information (Details) HTML 29K
50: R40 Income Taxes - Narrative (Detail) HTML 27K
51: R41 Other Operating Charges, net (Details) HTML 58K
52: R42 Non-operating Income (Expense) (Details) HTML 38K
53: R43 Pension and Other Postretirement Employee Benefit HTML 50K
Plans - Narrative (Detail)
54: R44 Accumulated Other Comprehensive Loss (Details) HTML 42K
55: R45 Stockholders' Equity - (Detail) HTML 42K
56: R46 Earnings per Common Share - Reconciliation of HTML 40K
Number of Common Shares Used in Calculating Basic
and Diluted Net Earnings Per Share (Detail)
57: R47 Segment Information (Detail) HTML 47K
58: R9999 Uncategorized Items - clw-20200930.htm HTML 19K
60: XML IDEA XML File -- Filing Summary XML 108K
10: XML XBRL Instance -- clw-20200930_htm XML 1.49M
59: EXCEL IDEA Workbook of Financial Reports XLSX 62K
6: EX-101.CAL XBRL Calculations -- clw-20200930_cal XML 174K
7: EX-101.DEF XBRL Definitions -- clw-20200930_def XML 400K
8: EX-101.LAB XBRL Labels -- clw-20200930_lab XML 1.01M
9: EX-101.PRE XBRL Presentations -- clw-20200930_pre XML 649K
5: EX-101.SCH XBRL Schema -- clw-20200930 XSD 101K
61: JSON XBRL Instance as JSON Data -- MetaLinks 283± 392K
62: ZIP XBRL Zipped Folder -- 0001504337-20-000033-xbrl Zip 209K
(Exact name of registrant as specified in its charter)
iDelaware
i20-3594554
(State
or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
i601 West Riverside,
iiSuite
1100/
i99201
iSpokane,
iWA
(Address
of principal executive offices)
(Zip Code)
(i509) i344-5900
(Registrant’s telephone number, including area code)
__________________________________
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon Stock, par value $0.0001 per share
iCLW
iNew
York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. iYes ý No ¨
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). iYes ý No ¨
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,”“smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
iAccelerated
filer
ý
Non-accelerated filer
¨
Smaller reporting company
i¨
Emerging growth company
i¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes i¨ No ý
Our disclosure, discussion and analysis in this report contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding impacts of COVID-19 on our business and operations; accounting standards; liquidity; capital expenditures; cash flow; borrowing and credit facilities; credit agreement compliance; disclosure controls and legal proceedings. Words such as anticipate, expect, intend, plan, target, project, believe, schedule, estimate, may, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, assumptions and projections that are subject to change. Our actual results of operations may differ materially from those expressed or implied by the forward-looking statements contained
in this report. Important factors that could cause or contribute to such differences include those risks discussed in the section entitled “Risk Factors” in our 2019 Form 10-K and the "Risk Factor" included in Part II of this report, as well as the following:
•impact of COVID-19 on our operations, our suppliers' operations and our customer demand;
•competitive pricing pressures for our products, including as a result of increased capacity as additional manufacturing facilities are operated by our competitors and the impact of foreign currency fluctuations on the pricing of products globally;
•the loss of, changes in prices in regard to, or reduction in, orders from a significant customer;
•changes
in the cost and availability of wood fiber and wood pulp;
•changes in transportation costs and disruptions in transportation services;
•changes in customer product preferences and competitors' product offerings;
•larger competitors having operational and other advantages;
•customer acceptance and timing and quantity of purchases of our tissue products, including the existence of sufficient demand for and the quality of tissue produced by our expanded Shelby, North Carolina operations;
•consolidation and vertical integration of converting operations in the paperboard industry;
•our
ability to successfully implement our operational efficiencies and cost savings strategies, along with related capital projects, and achieve the expected operational or financial results of those projects, including from the continuous digester at our Lewiston, Idaho facility;
•changes in the U.S. and international economies and in general economic conditions in the regions and industries in which we operate;
•manufacturing or operating disruptions, including IT system and IT system implementation failures, equipment malfunctions and damage to our manufacturing facilities;
•cyber-security risks;
•changes in costs for and availability of packaging supplies, chemicals, energy and maintenance and repairs;
•labor
disruptions;
•cyclical industry conditions;
•changes in expenses, required contributions and potential withdrawal costs associated with our pension plans;
•environmental liabilities or expenditures;
•reliance on a limited number of third-party suppliers for raw materials;
•our ability to attract, motivate, train and retain qualified and key personnel;
•our substantial indebtedness and ability to service our debt obligations;
•restrictions on our business from debt covenants and terms;
•negative
changes in our credit agency ratings; and
•changes in laws, regulations or industry standards affecting our business.
Forward-looking statements contained in this report present management’s views only as of the date of this report. Except as required under applicable law, we do not intend to issue updates concerning any future revisions of management’s views to reflect events or circumstances occurring after the date of this report.
See
accompanying Notes to the Consolidated Financial Statements.
7
Clearwater Paper Corporation
Notes to Consolidated Financial Statements
(Unaudited)
NOTE i1
BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments) necessary to present fairly, in all material respects, the consolidated financial position, results of operations, stockholders' equity and cash flows for us and our subsidiaries for the interim periods presented. Results of operations for interim periods are not necessarily indicative of results to be expected for an entire year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31,
2019. All dollar amounts are shown in millions, except per share.
NOTE 2 iRECENTLY ADOPTED AND NEW ACCOUNTING STANDARDS
Recently Adopted Accounting Standards
In March 2020, the SEC issued a final rule that amended the disclosure requirements under
SEC Regulation S-X Rule 3-10, Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered. The final rule is based on the premise that the primary source of information that investors in guaranteed debt rely on is the consolidated financial statements of the parent company. The final rule replaces the previous requirement to provide separate condensed consolidating financial information of the guarantors. The final rule is effective for filings on or after January 4, 2021, and early adoption is permitted. We have elected to early adopt this rule which resulted in the removal of the supplemental guarantor financial information.
New Accounting Standards
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic
848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides practical expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. This ASU is applicable to our contracts that reference LIBOR. The amendments may be applied through December 31, 2022. We will apply this guidance to transactions and modifications of these arrangements going forward.
We reviewed all other new accounting pronouncements issued in the period and concluded that they are not applicable or not material to our business.
NOTE
3 iFAIR VALUE MEASUREMENTS
Carrying amounts reported on the balance sheet for cash and cash equivalents, restricted cash, accounts receivable and accounts payable approximate fair value due to the short-term maturity of these instruments.
The fair value of our debt is included in the following table:
We have operating leases for manufacturing, office, warehouse and distribution space, paperboard sheeting and chipping facilities, equipment and vehicles. We also have finance leases related to our North Carolina converting and manufacturing facilities, as well as for certain office and other equipment. Our leases have remaining lease terms from less than one to ieleven
years, and some of our leases include one or more options to renew.
The tables below present financial information associated with our leases.
At
September 30, 2020, we were in compliance with covenants in our various credit agreements. The maturity of our Term Loan Agreement is subject to the refinancing of our 2014 Notes. If the 2014 Notes are not refinanced 91 days before their maturity, the Term Loan Credit Agreement will become due.
During the third quarter of 2020, in connection with the issuance of the 2020 Notes, we redeemed the 2013 Notes in full. This redemption resulted in a loss on early debt extinguishment of $i3.2 million
consisting of $i1.2 million related to the write off unamortized debt cost along with the premium on debt redemption of $i2.1 million.
Term Loan Credit Agreement
The Term Loan Credit Agreement matures on July 26, 2026. We are required to repay the aggregate outstanding principal amount in quarterly installments in an aggregate amount for each such date equal to the aggregate principal amount of the initial loan amount (as such amount may be adjusted pursuant to the prepayment provisions of the Term Loan Credit Agreement) multiplied by i0.25%. Through the
third quarter of 2020, we have made voluntary prepayments of $100 million. These prepayments were applied against our quarterly required installments through 2026. In connection with the voluntary repayments, we recorded $i1.6 million in early debt extinguishment related to the write off of associated deferred debt fees.
In addition, we must make mandatory prepayments of principal under the Term Loan Credit Agreement upon the occurrence of certain specified events, including certain asset sales
(subject to customary reinvestment rights), debt issuances not permitted under the Term Loan Credit Agreement, and based on a percentage, which may vary from i0% to i50%
depending on our secured leverage ratio, of annual Excess Cash Flows in excess of certain threshold amounts, less any voluntary prepayments under the Term Loan Credit Agreement. Any remaining outstanding principal balance under the Term Loan Credit Agreement is repayable on the maturity date. Amounts repaid or prepaid by us with respect to the loans under the Term Loan Credit Agreement cannot be reborrowed. We may, at our option, prepay any borrowings under the Term Loan Credit Agreement, in whole or in part, at any time and from time to time without premium or penalty (except in certain circumstances).
We may add one or more incremental term loan facilities to the Term Loan Credit Agreement, subject to obtaining commitments from any participating lenders and certain other conditions, in an amount not to exceed (1) $i100
million, plus (2) the amount of all voluntary prepayments of the Term Loan Credit Agreement (other than prepayments funded with long-term indebtedness), plus (3) an additional amount, so long as after giving effect to the incurrence of such additional amount, our pro forma first lien secured leverage ratio would not exceed i2.00x to 1.00x. At September 30, 2020 our pro forma first lien secured ratio was i0.65x. Under
the Term Loan Credit Agreement, loans generally may bear interest based on LIBOR or an annual base rate, as applicable, plus, in each case, an applicable margin. When our leverage ratio is (i) less
11
than or equal to i4.25 to 1.00, the margin is i3.00%
per annum in the case of LIBOR loans and of i2.00% per annum in the case of annual base rate loans and (ii) greater than i4.25 to 1.00, the margin is i3.25%
per annum in the case of LIBOR loans and of i2.25% per annum in the case of annual base rate loans. At September 30, 2020, our leverage ratio was i2.80x and therefore our applicable
margin on LIBOR loans was i3.00%.
ABL Credit Agreement
The ABL Credit Agreement matures on July 26, 2024 and includes a $250 million revolving loan commitment, subject to borrowing base limitations based on a percentage of applicable eligible receivables and eligible inventory. Based upon our Consolidated Balance Sheet as of September 30, 2020, our borrowings supported up to $i234.2
million availability under the line of which no borrowings were outstanding and $i4.4 million was utilized to issue letters of credit. We may, at our option, prepay any borrowings under the ABL Credit Agreement, in whole or in part, at any time and from time to time without premium or penalty (except in certain circumstances). Borrowings under the ABL Credit Agreement are also subject to mandatory prepayment in certain circumstances, including in the event that borrowings exceed applicable borrowing base limits. We may also increase commitments under the ABL Credit Agreement in an aggregate principal
amount of up to $i100 million, subject to obtaining commitments from any participating lenders and certain other conditions.
The ABL Credit Agreement also contains a financial covenant, which requires us to maintain a consolidated fixed charge coverage ratio of not less than i1.10
to 1.00, provided that the financial covenant under the ABL Credit Agreement is only applicable when unused availability falls below $25 million. As of September 30, 2020, our fixed charge coverage ratio was approximately 4.31x which included the impact of our voluntary debt prepayments. Our ability to utilize our ABL Credit Agreement could be limited in the future by our bond indentures which have limitations on liens.
2020 Notes
In 2020, we issued $i275
million aggregate principal amount of senior notes (2020 Notes) due August 2028 with an interest rate of i4.75%.
The Notes are unsecured and effectively subordinated to all of the Company’s existing and future secured debt, including borrowings under its existing credit facilities. The Notes are guaranteed on an unsecured basis by each of the
Company’s existing direct and indirect domestic subsidiaries, and will be guaranteed by each of the Company’s future direct and indirect domestic subsidiaries, subject to certain exceptions. If the Company is unable to make payments on the Notes when they are due, each Guarantor is obligated to make such payments.
The Indenture contains covenants that, among other things, limit our ability and the ability of any of our subsidiaries
to (i) enter into sale leaseback transactions, (ii) incur liens and (iii) consolidate, merge or sell all or substantially all of our assets. In addition, the Indenture requires, among other things, we provide certain reports to holders of the Notes. These covenants are subject to a number of exceptions, limitations and qualifications as set forth in the Indenture.
We may redeem all or a portion of the 2020 notes at specified redemption prices plus accrued and unpaid interest. In addition, we may be required to make an offer to purchase the 2020 Notes upon the sale of certain assets and upon a change in control.
NOTE
8 iINCOME TAXES
For interim periods, accounting standards require that income tax expense be determined by applying the estimated annual effective income tax rate to year-to-date results, unless this method does not result in a reliable estimate of year-to-date income tax expense. Each period, the income tax accrual is adjusted to the latest estimate and the difference from the previously accrued year-to-date balance is adjusted to the current quarter.
For the nine months ended September
30, 2020, our income tax expense reflects an effective rate of i21% as compared to an effective rate of i38% in the comparable period of 2019. For
the first nine months of 2020, the effective rate of i21% approximated the U.S. statutory tax rate. In this period, we recognized a $i7.0 million benefit from the
provisions of the Coronavirus Aid, Relief, and Economic Security Act. For the nine months ended September 30, 2019, the primary differences between the U.S. federal statutory rate of i21% and the effective rate of i38%
relates to the effect of tax credits and state tax rate changes.
12
NOTE 9 OTHER OPERATING CHARGES
The major components of “Other operating charges, net” in the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 are reflected in the table below and described in the paragraphs following the table:
During
the third quarter of 2020, we recorded $iii0.3//
million of expenses in "Other operating charges, net." The component of the expense includes:
•expense of $i0.3 million relating to directors' equity based compensation.
During the second quarter of 2020, we recorded $i3.0
million of expenses in "Other operating charges, net." The components of the expenses include:
•expenses of $i0.6 million related to reorganization expenses (primarily related to corporate expenses),
•expense of $i1.9
million relating to directors' equity based compensation.
i
During the first quarter of 2020, we recorded $i8.5 million of expenses
in "Other operating charges, net." The components of the expenses include:
•expenses of $i2.8 million related to reorganization expenses (primarily related to corporate expenses),
•expenses of $i6.6
million associated with union settlement retroactive wage payments ($i2.6 million associated with Consumer Products and $i4.0 million associated with
Paperboard segments),
•gain of $i1.4 million associated with the Ladysmith Consumer Products facility sale escrow release, and
•expense of $i0.2
million relating to directors' equity based compensation.
/
NOTE 10 iNON-OPERATING INCOME (EXPENSE)
The components of “Non-operating expense” in the Consolidated Statements
of Operations for the three and nine months ended September 30, 2020 and 2019 are reflected in the table below:
Non-operating
pension and other postretirement employee benefits expense
(i1.9)
(i1.4)
(i5.7)
(i4.3)
Total
non-operating expense
$
(i17.9)
$
(i17.2)
$
(i47.5)
$
(i39.5)
/
13
NOTE
11 PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
i
The following table details the components of net periodic cost of our company-sponsored pension and other postretirement employee benefit plans for the periods presented:
Three
Months Ended September 30,
Nine Months Ended September 30,
Pension Benefit Plans
2020
2019
2020
2019
Service cost
$
i0.5
$
i0.6
$
i1.7
$
i1.8
Interest
cost
i2.6
i3.1
i7.8
i9.3
Expected
return on plan assets
(i3.8)
(i4.1)
(i11.3)
(i12.4)
Amortization
of actuarial loss
i2.4
i1.8
i7.4
i5.5
Net
periodic cost
$
i1.7
$
i1.4
$
i5.6
$
i4.3
Three
Months Ended September 30,
Nine Months Ended September 30,
Other Postretirement Employee Benefit Plans
2020
2019
2020
2019
Service cost
$
i—
$
i—
$
i0.1
$
i0.1
Interest
cost
$
i0.6
$
i0.7
$
i1.8
$
i2.1
Amortization
of actuarial loss (gain)
i—
(i0.1)
i—
(i0.3)
Net
periodic cost
$
i0.7
$
i0.6
$
i1.8
$
i1.9
/
iWe
record the service component of net periodic cost (benefit) as part of "Cost of sales" and "Selling, general, and administrative expenses," while the non-service components of net periodic cost (benefit) are recorded to "Other non-operating expense" on our Consolidated Statements of Operations. For the three and nine months ended September 30, 2020, we recorded $i0.3
million and $i1.1 million to "Cost of sales" and $i0.2
million and $i0.7 million to "Selling, general, and administrative expenses". For the three and nine months ended September 30, 2019, we recorded $i0.4
million and $i1.1 million to "Cost of sales" and $i0.3
million and $i0.8 million to "Selling, general, and administrative expenses"./
NOTE
12 iACCUMULATED OTHER COMPREHENSIVE LOSS
i
Accumulated
other comprehensive loss, net of tax, is comprised of the following:
Pension Plan Adjustments
Other Post Retirement Employee Benefit Plan Adjustments
We have stock-based compensation plans under which restricted stock awards and stock options are granted according to time or performance vesting requirements. At September 30, 2020, approximately i1.3 million
shares were available for future issuance under our current plan.
Total stock-based compensation expense (selling, general and administrative and other operating charges, net)
$
i2.5
$
i0.9
$
ii7.3/
$
iii3.0//
Income
tax benefit related to stock-based compensation
$
i0.6
$
i0.2
$
i1.9
$
i0.8
Impact
on cash flow due to taxes paid related to net share settlement of equity awards
$
i—
$
i—
$
i0.7
$
i0.4
At
September 30, 2020, $i12.7 million of compensation cost related to unvested restricted stock units, performance awards and stock options attributable to future service had not yet been recognized.
During the first nine months ended September 30, 2020, we granted i377,822
restricted stock units (time vesting) at an average grant date fair value of $i23.46 per share and i120,382
restricted stock units (performance vesting) at an average grant date fair value of $i27.67.
NOTE 14 iEARNINGS
PER SHARE
Basic income (loss) per share is based on the weighted-average number of shares of common stock outstanding. Diluted income (loss) per share is based upon the weighted-average number of shares of common stock outstanding plus all potentially dilutive securities that were assumed to be converted into common shares at the beginning of the period under the treasury stock method.
i
Three
Months Ended September 30,
Nine Months Ended September 30,
(In thousands)
2020
2019
2020
2019
Basic weighted-average common shares outstanding1
i16,595
i16,539
i16,581
i16,531
Incremental
shares due to:
Stock-based awards
i188
i—
i107
i—
Diluted
weighted-average common shares outstanding
i16,783
i16,539
i16,689
i16,531
1Basic
weighted-average common shares outstanding includes restricted stock unit awards that are fully vested, but are deferred for future issuance.
/
Anti-dilutive shares excluded from the calculation were i0.4 million and i1.1
million for the three months ended September 30, 2020 and 2019 and i0.6 million and i1.0
million for the nine months ended September 30, 2020 and 2019.
NOTE 15 iSEGMENT INFORMATION
We operate in two segments: Consumer Products and Paperboard. Our business units have been aggregated into these two segments based upon the similarity of economic characteristics,
customers and distribution methods. Our results of operations are summarized below for each of these segments separately. Segment information was prepared in accordance with the same accounting principles as those described in Note 1 of the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
Impact of COVID-19 on Our Business
In response to the outbreak and business disruption caused by the novel coronavirus (COVID-19) pandemic, we are focused on two priorities - the health and safety of our employees and continuing to safely operate our facilities to meet the needs of our customers. We have implemented important health and safety measures across our facilities, including temperature checks, social distancing guidelines, quarantine protocols, sanitation practices, remote work for those whose jobs allow them to do so, and travel and visitor restrictions.
The COVID-19
pandemic has resulted, and is likely to continue to result, in significant economic disruption and may adversely affect our business. To date, our industry has been classified as essential by the Federal Government, through the Department of Homeland Security’s Cyber and Infrastructure Security Agency (CISA), and in each of the jurisdictions in which we operate, which enabled us to operate our facilities through the first nine months of 2020. We do not expect there to be any changes in this designation and as a result, we do not anticipate having to curtail or cease our operations due to any governmental imposed shutdown.
Our company and our competitors have experienced a significant increase in demand for "at home" tissue products in the first nine months of 2020 as a result of COVID-19. We expect that demand for tissue will normalize
and will eventually return to pre-COVID-19 levels. Demand for paperboard products has also been affected by the COVID-19 pandemic, with increases in some end-market segments like food packaging and decreases in food service and commercial print.
The effects of the COVID-19 pandemic may negatively impact various aspects of our business including, but not limited to:
•the ability of our suppliers to meet delivery requirements and commitments;
•disruptions to our supply chains;
•the ability of our employees to perform their work due to illness caused by the pandemic, the complete or partial closure of one or more of our manufacturing facilities, or local, state, or federal orders requiring employees to remain at home and;
•disruptions or delays in the delivery of our products to customers;
•a decrease in demand for our products;
•disruptions in our manufacturing operations due to localized conditions;
•limitations on the ability of our customers to pay us on a timely basis; and
•negative impact on some of our customers due to challenging economic conditions.
We are evaluating and taking actions to monitor and ensure appropriate levels of available liquidity and may experience disruptions in our business as we implement modifications to preserve adequate liquidity and ensure that our business can continue
to operate during this uncertain time. However, we believe that our cash flows from operations, our cash on hand and our borrowing capacity under our credit agreements will be adequate to fund debt service requirements and provide cash to support our ongoing operations, capital expenditures and working capital needs for the next twelve months.
As the COVID-19 pandemic continues to evolve, we will continue to actively monitor the situation and may take actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our employees, customers, suppliers, and shareholders.
Executive Summary
We recorded an increase of 3% in net sales to $457.4 million for the three months ended September 30, 2020 compared to
$445.2 million for the three months ended September 30, 2019. We recorded net income for the three months ended September 30, 2020 of $21.4 million, or $1.28 per diluted share, compared to net loss of $11.0 million or $0.66 per diluted share in the third quarter of 2019. We recorded Adjusted EBITDA for the three months ended September 30, 2020 of $77.2 million compared to $31.5 million in the third quarter of 2019.
We recorded an increase of 7% in net sales to $1.4 billion for the nine months ended September 30, 2020 compared to $1.3 billion in the nine months ended September 30, 2019. We recorded net income for the nine months ended September
30, 2020 of $54.5 million, or $3.27 per diluted share, compared to net loss of $7.6 million or $0.46 per diluted share in the
17
nine months ended September 30, 2019. We recorded Adjusted EBITDA for the nine months ended September 30, 2020 of $211.6 million compared to $115.6 million in the first nine months of 2019.
The increase in net sales, net income and Adjusted EBITDA for both the three and nine month periods ended September 30, 2020 was primarily driven by a significantly higher sales volume for retail tissue as a result of the COVID-19 pandemic. Increased demand resulted
in increased production which in turn drove increased fixed cost absorption and improved margins. Each period also benefited on a comparative basis due to the absence of major maintenance in our pulp operations.
See discussion on segment level results regarding net sales, operating results and Adjusted EBITDA in “Our Operating Results” below.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in accordance with GAAP requires our management to select and apply accounting policies that best provide the framework to report our results of operations and financial position. The selection and application of those policies requires management to make difficult, subjective and complex judgments
concerning reported amounts of revenue and expenses during the reporting period and the reported amounts of assets and liabilities at the date of the financial statements. As a result, it is possible that materially different amounts would be reported under different conditions or using different assumptions.
As of September 30, 2020, there have been no significant changes with regard to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.
NON-GAAP MEASURES
In evaluating our business, we utilize several non-GAAP financial measures. A non-GAAP financial measure is generally defined by the SEC as one that purports to measure historical
or future financial performance, financial position or cash flows, but excludes or includes amounts that would not be so excluded or included under applicable GAAP guidance. In this report on Form 10-Q, we disclose overall and segment earnings (loss) from operations before interest expense, net, non-operating pension and other postretirement benefit costs, taxes, depreciation and amortization, goodwill impairment, other operating charges, net, and debt retirement costs as Adjusted EBITDA which is a non-GAAP financial measure. Adjusted EBITDA is not a substitute for the GAAP measure of net income or for any other GAAP measures of operating performance.
We have included Adjusted EBITDA on a consolidated and segment basis in this report because we use them as important supplemental measures of our performance and believe that they are frequently used by securities analysts, investors and other interested persons in the evaluation
of companies in our industry, some of which present Adjusted EBITDA when reporting their results. We also use Adjusted EBITDA to evaluate our performance as compared to other companies in our industry that have different financing and capital structures and/or tax rates. It should be noted that companies calculate Adjusted EBITDA differently and, therefore, our Adjusted EBITDA measures may not be comparable to Adjusted EBITDA reported by other companies. Our Adjusted EBITDA measures have material limitations as performance measures because they exclude interest expense, income tax (benefit) expense and depreciation and amortization which are necessary to operate our business or which we otherwise incur or experience in connection with the operation of our business. In addition, we exclude other income and expense items which are outside of our core operations.
18
The
following table provides our Adjusted EBITDA for the periods presented, as well as a reconciliation to net income.
Three Months Ended September 30,
Nine Months Ended September 30,
(In millions)
2020
2019
2020
2019
Net
income (loss)
$
21.4
$
(11.0)
$
54.5
$
(7.6)
Income tax provision
9.9
(8.7)
14.1
(4.7)
Interest
expense, net
12.2
13.1
37.0
32.5
Depreciation and amortization expense
27.7
32.0
83.5
86.3
Other
operating charges, net
0.3
1.9
11.9
2.1
Other non-operating expense
1.9
1.4
5.7
4.3
Debt
retirement costs
3.9
2.7
4.8
2.7
Adjusted EBITDA
$
77.2
$
31.5
$
211.6
$
115.6
Consumer
Products segment income (loss)
$
31.3
$
(4.4)
$
82.1
$
(8.3)
Depreciation and amortization
17.1
19.0
51.4
51.2
Adjusted
EBITDA Consumer Products segment
$
48.3
$
14.6
$
133.6
$
42.9
Paperboard segment income
$
32.8
$
17.1
$
91.6
$
80.1
Depreciation
and amortization
9.2
11.2
27.6
30.1
Adjusted EBITDA Paperboard segment
$
42.0
$
28.3
$
119.2
$
110.2
Corporate
and other expense
$
(14.6)
$
(13.2)
$
(45.6)
$
(42.5)
Depreciation and amortization
1.5
1.8
4.4
5.0
Adjusted
EBITDA Corporate and other
$
(13.1)
$
(11.4)
$
(41.2)
$
(37.5)
Consumer Products segment
$
48.3
$
14.6
$
133.6
$
42.9
Paperboard
segment
42.0
28.3
119.2
110.2
Corporate and other
(13.1)
(11.4)
(41.2)
(37.5)
Adjusted EBITDA
$
77.2
$
31.5
$
211.6
$
115.6
19
OUR
OPERATING RESULTS
Our results of operations for each of our segments are discussed below. See Note 15 "Segment Information" of the Notes to the Consolidated Financial Statements included in Item 1 of this report for further information regarding our segments.
Consumer Products
Three
Months Ended September 30,
Nine Months Ended September 30,
(Dollars in millions, except per unit)
2020
2019
Increase (decrease)
2020
2019
Increase (decrease)
Sales:
Retail
tissue
$
238.6
$
215.3
10.9
%
$
747.1
$
630.4
18.5
%
Non-retail tissue
6.9
12.4
(44.3)
%
31.0
43.2
(28.2)
%
Other
2.8
0.9
n.m.
11.0
2.7
n.m.
$
248.3
$
228.5
8.7
%
$
789.1
$
676.2
16.7
%
Operating
income (loss)
$
31.3
$
(4.4)
n.m.
$
82.1
$
(8.3)
n.m.
Operating margin
12.6
%
(1.9)
%
10.4
%
(1.2)
%
Adjusted
EBITDA
$
48.3
$
14.6
230.8
%
$
133.6
$
42.9
211.3
%
Adjusted EBITDA margin
19.5
%
6.4
%
16.9
%
6.3
%
Shipments
(short tons)
Retail
86,292
79,526
8.5
%
272,515
229,057
19.0
%
Non-retail
3,799
6,882
(44.8)
%
18,613
23,771
(21.7)
%
90,091
86,408
4.3
%
291,128
252,828
15.1
%
Cases
(in thousands)
14,507
13,162
10.2
%
45,727
37,970
20.4
%
Sales
price (per short ton)
Retail
$
2,766
$
2,707
2.2
%
$
2,741
$
2,752
(0.4)
%
Non-retail
1,820
1,805
0.8
%
1,665
1,815
(8.3)
%
n.m.
- not meaningful
Sales volumes increased in our Consumer Products segment for the three and nine month periods ended September 30, 2020 compared to the same periods in the prior year due to significantly higher sales volume for retail tissue as a result of the COVID-19 pandemic and increases in demand based upon new customer programs which were implemented prior to the COVID-19 pandemic. Sales prices changed in our Consumer Products segment for the three and nine month periods ended September 30, 2020 compared to the same periods in the prior year due primarily to changes in product mix. From a product perspective, in the third quarter of 2020 compared to the third quarter of 2019, we saw the largest increases in bath tissue and paper towels and for the nine months ended September
30, 2020 as compared to the nine months ended September 30, 2019, we saw the largest increases in bath tissue. As a percentage of our Consumer Products segment, paper towel and bath tissue represent more than 80% of our business. Due to the COVID-19 pandemic, we have seen a significant reduction in our non-retail business due to the COVID-19 pandemic which is primarily driven by away-from-home products.
Overall, the increase in operating income and Adjusted EBITDA for the three and nine month periods ended September 30, 2020 compared to the same periods in the prior year was driven by higher sales as noted above as well as improvement in margin due to increased production that drove increased fixed cost absorption. Additionally, we realized lower input costs, primarily in external pulp prices and freight costs.
20
Paperboard
Three
Months Ended September 30,
Nine Months Ended September 30,
(Dollars in millions, except per ton amounts)
2020
2019
Increase (decrease)
2020
2019
Increase (decrease)
Sales:
Paperboard
$
208.0
$
215.4
(3.4)
%
$
623.1
$
644.6
(3.3)
%
Other
1.1
1.3
(13.5)
%
3.6
5.2
(31.1)
%
$
209.1
$
216.6
(3.5)
%
$
626.6
$
649.7
(3.6)
%
Operating
income
32.8
17.1
92.1
%
91.6
80.1
14.3
%
Operating margin
15.7
%
7.9
%
14.6
%
12.3
%
Adjusted
EBITDA
$
42.0
$
28.3
48.6
%
$
119.2
$
110.2
8.1
%
Adjusted EBITDA margin
20.1
%
13.0
%
19.0
%
17.0
%
Shipments
(short tons)
211,820
214,537
(1.3)
%
630,526
642,559
(1.9)
%
Sales price (per short ton)
$
982
$
1,004
(2.2)
%
$
988
$
1,003
(1.5)
%
Sales
volumes decreased in our Paperboard segment for the three and nine month periods ended September 30, 2020 compared to the same periods in the prior year due to impacts of COVID-19 which led to a reduction in our commodity food service business offset by increases in our folding carton and coated cup business. Sales prices decreased in our Paperboard segment for the three and nine month periods ended September 30, 2020 compared to the same periods in the prior year due to the impacts of price reductions. During the third quarter of 2019, the Paperboard division completed its planned major maintenance which resulted in higher operating costs during that quarter.
Overall, the increase in operating income and Adjusted EBITDA for the three and nine month periods ended September 30, 2020
as compared to the same periods in the prior year was driven by reduced sales offset by improved input costs, primarily consisting of natural gas, wood and pulp and absence of planned major maintenance during the quarter and nine months ended September 30, 2020.
Corporate expenses
Corporate expenses for the three and nine month periods ended September 30, 2020 were $14.6 million and $45.6 million compared to $13.2 million and $42.5 million in the same periods in the prior year. The increases for the three and nine month periods ended September 30, 2020 were related to higher incentive pay due to improved results and increased costs associated with professional services. Corporate expenses primarily consist of corporate overhead such
as wages and benefits, professional fees, insurance and other expenses for corporate functions including certain executive officers, public company costs, information technology, financial services, environmental and safety, legal, supply management, human resources and other corporate functions not directly associated with the business operations.
Other operating charges
See Note 9 "Other operating charges" of the Notes to the Consolidated Financial Statements included in Item 1 of this report for additional information.
Interest expense
Interest expense for the three month period ended September 30, 2020 compared to the same period in the prior year was $0.9 million lower due to lower debt outstanding. Interest expense for the nine months
ended September 30, 2020 compared to the same period in the prior year was $4.6 million higher due to lower capitalized interest due to the completion of our Shelby expansion in the latter portion of 2019. See Note 10 "Non-operating income (expense)" of the Notes to the Consolidated Financial Statements included in Item 1 of this report for additional information.
21
LIQUIDITY AND CAPITAL RESOURCES
Our principal sources of liquidity are existing cash balances, cash generated by our operations and our ability to borrow under such credit facilities as we may
have in effect from time to time. Our principal uses of liquidity are paying the costs and expenses associated with our operations, servicing outstanding indebtedness and making capital expenditures. We may also from time to time prepay or repurchase outstanding indebtedness (including by issuing new indebtedness subject to market conditions to refinance such outstanding indebtedness) or acquire assets or businesses that are complementary to our operations.
Operating Activities
Net cash flows provided by operating activities for the nine months ended September 30, 2020 were $176.1 million compared to a use of cash of $16.2 million in the first nine months of 2019. This increase was driven by increases in our net income and changes in working capital due to increased demand in our consumer products division which resulted in lower
inventories. Accounts receivable and accounts payable agings have remained relatively consistent with balances as of December 31, 2019.
Investing Activities
During the nine months ended September 30, 2020, net cash flows used in investing activities was $27.5 million compared to $125.8 million in the prior year period. This decrease is primarily due to the completion of our Shelby expansion in late 2019. Included in "Other accrued liabilities" on our Consolidated Balance Sheets was $4.6 million and $28.7 million related to capital expenditures that had not yet been paid at September 30, 2020 and 2019.
Throughout 2020, we expect cash paid
for capital expenditures to be at or below $45 million.
Financing Activities
Net cash flows used by financing activities were $122.5 million for the nine months ended September 30, 2020 as compared to cash provided by financing activities of $127.4 million for the same period of 2019. The change was driven by improved operating results and lower capital expenditures, resulting in additional available cash to fund debt repayments in the first nine months of 2020.
Credit Agreements
We must make mandatory prepayments of principal under the Term Loan Credit Agreement upon the occurrence of certain specified events, including based upon a percentage of annual Excess Cash Flow and Senior Secured Leverage
Ratio as defined by the Term Loan Credit Agreement. There is uncertainty in the amount of Excess Cash Flow that we may generate during the current fiscal year, therefore, we are unable to estimate the mandatory prepayment under the Term Loan Credit Agreement that could be required at the time such payment is due in 2021. The $100 million prepayment of principal under the Term Loan Credit Agreement in the first nine months of 2020 will offset the mandatory prepayment that would otherwise be required on account of the existence of Excess Cash Flow. As long as the Senior Secured Leverage Ratio on the last day of the fiscal year is below 1.50x, we are not subject to an excess cash flow repayment. Amounts repaid or prepaid cannot be reborrowed. However, we may add one or more incremental term loan facilities to the Term Loan Credit Agreement, subject to obtaining commitments from any participating lenders and certain other conditions, so long as our first lien secured leverage
ratio does not exceed 2.00x to 1.00. At the end of the third quarter of 2020, our first lien secured ratio was 0.65x.
The ABL Credit Agreement includes a $250 million revolving loan commitment, subject to borrowing base limitations. Borrowings under the ABL Credit Agreement are subject to mandatory prepayment in certain circumstances. We may also increase commitments under the ABL Credit Agreement in an aggregate principal amount of up to $100 million, subject to obtaining commitments from any participating lenders and certain other conditions.
Both credit agreements contain certain customary representations, warranties, and affirmative and negative covenants. The ABL Credit Agreement also contains a financial covenant, which requires us to maintain a consolidated fixed charge coverage ratio of not less than 1.10x to 1.00x, provided that the financial covenant under the ABL Credit
Agreement is only applicable when availability falls below $25 million.
At September 30, 2020, we were in compliance with all covenants in both of our credit agreements, and based on our current financial projections, we expect to remain in compliance. However, if our financial position, results of operations or market conditions deteriorate, we may not be able to remain in compliance. There can be no assurance that we will be able to remain in compliance with our credit agreements. If we are unable to do so, it would be necessary to seek an amendment from our lenders, which, if obtained, could require payment of additional fees, increased interest rates or other conditions or restrictions.
22
ITEM 3.
Quantitative
and Qualitative Disclosures About Market Risk
Interest Rate Risk
Our exposure to market risks on financial instruments includes interest rate risk on our Term Loan Credit Agreement and ABL Credit Agreement. As of September 30, 2020, there were $199.3 million in borrowings outstanding under our credit agreements. The reference interest rate applied to borrowings under the Credit Agreements is adjusted, at our option, at one, two, three, or six month intervals for LIBOR-based borrowings (or daily in the case of alternative based rate borrowings). A one percentage point increase or decrease in interest rates, based on outstanding credit facilities' borrowings of $199.3 million, would have an approximate $2.0 million annual effect on interest expense.
23
ITEM 4.
Controls
and Procedures
As of September 30, 2020, our Chief Executive Officer (CEO) and Chief Financial Officer (CFO) have carried out, with the participation of our Disclosure Committee and management, an evaluation of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the Act). Based upon this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to provide reasonable assurance that material information required to be disclosed by us in reports we file under the Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and that information required to be disclosed by us in the reports we file or submit under the Act is accumulated and communicated to our management,
including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the three months ended September 30, 2020 that has materially affected, or is likely to materially affect, our internal control over financial reporting.
24
Part II
ITEM 1.
Legal
Proceedings
We may from time to time be involved in claims, proceedings and litigation arising from our business and property ownership. We believe, based on currently available information, that the results of such proceedings, in the aggregate, will not have a material adverse effect on our financial condition.
ITEM 1A.
Risk Factors
The
COVID-19 pandemic may adversely affect our operations and financial condition.
Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.
The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across regional and global economies and financial markets. The outbreak of COVID-19 in many countries, including the United States, has adversely impacted global economic activity and has contributed to volatility and negative pressure in financial markets.
As has been widely reported
in the media, companies like ours experienced a significant increase in demand for tissue products in the first nine months of 2020 as a result of the COVID-19 pandemic, particularly due to residential consumer purchasing behavior. The stocking up of tissue products by residential consumers during the pandemic will likely lead to a drop in regular purchasing as the pandemic, or concerns as to tissue shortages as a result of the pandemic, subside. We expect that residential consumer demand will flatten and that sales of tissue products will eventually normalize in terms of annual volumes.
Nevertheless, our business, the businesses of our customers and the businesses of our suppliers could be materially and adversely affected by the impact and risks of the pandemic. Such risks include, but are not limited to, the following:
•the complete or partial closure
of one or more of our manufacturing facilities;
•limitations on our ability to operate our business as a result of any federal, state or local regulations, including any changes to the designation of our business as “essential” by the US Department of Homeland Security;
•disruptions to international trade, or further restrictions or prohibitions on international travel, on which we rely to make our products (for example, an interruption in eucalyptus pulp from Brazil or lack of availability for spare parts or technical support from European suppliers of our production and converting equipment);
•a decrease in demand for our products as a result of a prolonged economic downturn or global recession (for example, during previous, extreme recessionary periods
in the U.S., we experienced significant declines in demand for our paperboard used in folding carton, cup and liquid packaging applications);
•the interruption of our distribution system or delays in the delivery of our products;
•temporary or long-term disruption in our supply chains (for example, governmental restrictions on construction and the resulting decline in lumber production could result in a decline in the availability of wood residuals);
•volatility related to pension plan assets (for example, we may need to make additional contributions to address an increase in obligations and/or a loss in plan assets as a result of the combination of declining market interest rates and/or past or future plan asset investment losses);
•significant
disruption of global financial markets, which could have a negative impact on our ability to access capital in the future;
•a decline in our ability to collect on accounts receivable, which could materially affect our liquidity;
•bankruptcy of customers that leads to a decrease in demand for our products;
•the loss of our management team and employee base that possess unique technical skills for the execution of our business plan; and
•an interruption in processing or an inability to process accounts payable by our third-party processor, which could result in our suppliers and vendors withholding supplies or services.
The extent of the impact of the
COVID-19 pandemic on our business is highly uncertain and difficult to predict, as information is rapidly evolving with respect to the duration and severity of the pandemic. At this point, we cannot reasonably estimate the duration and severity of the COVID-19 pandemic, or its overall impact on our business. Moreover,
25
many of the risk factors set forth in our Form 10-K for the year ended December 31, 2019 should be interpreted as heightened risks as a result of the COVID-19 pandemic.
There are no other material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.
See Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, entitled “Risk Factors.”
In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibit 32 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such
certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.
27
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.